CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Olaratumab and doxorubicin for the treatment of metastatic soft tissue sarcoma: a retrospective case series
Joon Young Hur, Se Hoon Park, Su Jin Lee
Precis Future Med. 2019;3(2):77-84.   Published online May 30, 2019
DOI: https://doi.org/10.23838/pfm.2019.00016

Excel Download

Olaratumab and doxorubicin for the treatment of metastatic soft tissue sarcoma: a retrospective case series
Joon Young Hur, Se Hoon Park, Su Jin Lee
Precision and Future Medicine. 2019;3(2):77-84   Crossref logo
Link1 Link2 Link3
Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States
Santiago Zuluaga-Sanchez, Lisa M. Hess, Sorrel E. Wolowacz, Yulia D’yachkova, Emma Hawe, Adrian D. Vickers, James A. Kaye, David Bertwistle
Sarcoma. 2018;2018:1-14   Crossref logo
Link1 Link2 Link3
Outcome for Advanced or Metastatic Soft Tissue Sarcoma of Nonextremities Treated with Doxorubicin-Based Chemotherapy: A Retrospective Study from a Single Cancer Institution
Shoko Marshall, Kenji Nakano, Yoshiya Sugiura, Shinichiro Taira, Makiko Ono, Junichi Tomomatsu, Shunji Takahashi
Sarcoma. 2018;2018:1-7   Crossref logo
Link1 Link2 Link3
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
Alexandra Pender, Robin L Jones
Clinical Pharmacology: Advances and Applications. 2017;Volume 9:159-164   Crossref logo
Link1 Link2
Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy
Elizabeth J Davis, Rashmi Chugh
Drug Design, Development and Therapy. 2017;Volume 11:3579-3587   Crossref logo
Link1 Link2
Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model
Takashi Higuchi, Kentaro Miyake, Norihiko Sugisawa, Hiromichi Oshiro, Zhiying Zhang, Sahar Razmjooei, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Michael Bouvet, Shree Ram Singh, Hiroyuki Tsuchiya, Robert M. Hoffman
Cancer Letters. 2019;451:122-127   Crossref logo
Link1 Link2
Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal
Irina A. Tikhonova, Tracey Jones-Hughes, James Dunham, Fiona C. Warren, Sophie Robinson, Peter Stephens, Martin Hoyle
PharmacoEconomics. 2018;36(4):507-507   Crossref logo
Link1 Link2 Link3
Doxorubicin-Based Chemotherapy for the Palliative Treatment of Adult Patients with Locally Advanced or Metastatic Soft-Tissue Sarcoma: A Meta-Analysis and Clinical Practice Guideline
Vivien H. C. Bramwell, Dale Anderson, Manya L. Charette
Sarcoma. 2000;4(3):103-112   Crossref logo
Link1 Link2
Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas. The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
Ole S. Nielsen, Per Dombernowsky, Henning Mouridsen, Søren Daugaard, Martine Van Glabbeke, Anne Kirkpatrick, Jaap Verweij
Sarcoma. 2000;4(1-2):31-35   Crossref logo
Link1 Link2
866 Combination of doxorubicin/ifosfamide ± G-CSF in adult metastatic soft tissue sarcoma (STS)
H.J. Weh, M. de Wit, D.K. Hossfeld
European Journal of Cancer. 1995;31:S180-S181   Crossref logo
Link1 Link2